Phone: 866-310-7549 M-F 8AM-8PM ET Novo Nordisk, Inc. PO Box 370 Somerville, NJ 08876 Fax# 866-441-4190

Novo Nordisk Maine State Insulin Affordability Program Refill/Change Request Form



Asterisks indicate required field. Do not leave blank.

This form should be used by a health care practitioner to request a refill, to add a new medication, to request a change in medication or change in dosage for a current medication, OR to update the health care practitioner information, such as address, suite number, etc. Form must be submitted directly by the HCP and must include a cover letter/HCP letterhead to clearly identify HCP as the sender.

Patient First Name*:	Last Name*: Patient DOB*:		B * :					
Other Medications*:	Known Drug Allergies*:							
Patient's Street Address* (NO PO BOX):								
City: Note: ME residents who qualify for insulin under state in	sulin safety net	aws will h	ave their medication	State n shipped dired		Zip: eir home		
Patient ID Number: Patie			Patient's Email:	itient's Email:				
Licensed Health Care Practitioner In	formation							
Name*:			Designa	tion*:				
Street Address*:								
Suite/Building/Floor#:								
(NO PO BOX) City:				State	•	Zip:		
	State License N	lumber#	*:			State Where	Licensed:	
Fax*: Office Contact:			Office E	mail:				
NPI*: Days Office is Clo	sed for Delive	ries:	011100 2	····aiii				
Order Information	sed for Delive	103.						
order information	Max Dose/							
Product	Day (units)	Sig/Dire	ections (e.g., QD,	BID)	Formu	llation		Quantity
Fiasp® (insulin aspart) injection 100 U/mL					Vial	FlexTouch®	Cartridge	
Tresiba® (insulin degludec) injection U-100					Vial	FlexTouch®		
Insulin Degludec Injection U-100 (UB)					Vial	FlexTouch®		
Tresiba® (insulin degludec) injection U-200					Flex	Touch®		
Insulin Degludec Injection U-200 (UB)					Flex	Touch®		
NovoLog® (insulin aspart) injection 100 U/mL					Vial	FlexPen®	Cartridge	
Insulin Aspart Injection 100 U/mL (UB)					Vial	FlexPen®	Cartridge	
NovoLog® Mix 70/30 (insulin aspart protamine and insulin aspart injectable suspension) 100 U/mL					Vial	FlexPen®		
Insulin Aspart Protamine and Insulin Aspart Injectable Suspension Mix 70/30 100 U/mL (UB)					Vial	FlexPen®		
Novolin® R (insulin human injection) 100 U/mL					Vial			
Novolin® N (isophane insulin human suspension) 100 U/m	L				Vial			
Novolin® 70/30 (human insulin isophane suspension and human insulin injection) 100 U/mL					Vial			
NovoFine® 32G 6mm (100 needles/box)								
Zegalogue® (dasiglucagon) injection 0.6 mg/0.6 mLAuto-injector 1-packAuto-injector 1-packAuto-injector 2-packPrefilled Syringe 1-packPrefilled Syringe 2-pack						•		
NovoPen Echo®					1 pe	n		
By signing below, I acknowledge that I have re dispensed as written. (Handwritten/valid electro								
								SIGN

Phone: 866-310-7549 M-F 8AM-8PM ET Novo Nordisk, Inc. PO Box 370 Somerville, NJ 08876 Fax# 866-441-4190

Novo Nordisk Maine State Insulin Affordability Program Refill/Change Request Form



Asterisks indicate required field. Do not leave blank.

	_			
Pati	ent	Into)rm:	ation

Patient First Name*:	Last Name*:	Patient DOB*:
----------------------	-------------	---------------

Order Information (continued)

All orders will be filled with up to a **120-day** supply unless otherwise indicated by the prescriber. Prescribers, please complete the application with max daily dose and sig accordingly. **All reorder requests must be made directly by the prescriber to the Novo Nordisk Maine State Insulin Affordability Program.** FlexPen®/FlexTouch® are used with Novo Nordisk disposable needles. **Needles will not be sent as part of the order if they are not requested.**

Health Care Practitioner Declaration: "My signature certifies that I am a licensed health care practitioner eligible under state law to prescribe, receive, and dispense the requested medication(s) listed on the attached order, shipped from Novo Nordisk, and that I am not prohibited from participating in federally funded health care programs. If I am a Nurse Practitioner, Physician Assistant, Pharmacist, or PharmD, I certify that I am authorized and eligible in the state within which I am currently practicing to prescribe, receive, and dispense these products, and that I have my supervising Physician's approval to do so if required by law. NOTE: Prescribing practitioner information must match the practitioner's signature. I also certify that the product(s) being prescribed are to treat diagnosis(es) consistent with indication(s) and dosing described in the product's prescribing information. I further certify that all information provided in the Licensed Health Care Practitioner Information section is correct. I agree that medication(s) provided to me by Novo Nordisk for the applicant Information section will be provided by me to such eligible applicant for his or her own use without charge. I will not otherwise use any of such medications or prescribe, provide or dispense all or any portion thereof for the use of any other person. I consent that Novo Nordisk may contact the applicant named in the Applicant Information section for verification of applicant status and receipt of the indicated medication(s). I further consent that Novo Nordisk may, at its discretion and with adequate notice, perform an on-site audit/review solely related to Novo Nordisk State Insulin Program (the "Program") records related to the applicant named above on this application. I understand that I am not eligible to seek reimbursement for any medication dispensed by the Program, from any government program or third-party insurer. I also understand that eligibility under the Program is subject to Novo Nordisk's discretion and that Novo No